Arcellx (NASDAQ:ACLX – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Risk and Volatility Arcellx has a beta of -0.33, indicating […]
Arcellx, Inc. (NASDAQ:ACLX – Get Rating) major shareholder Sr One Capital Management, Llc sold 1,012,833 shares of the stock in a transaction that occurred on Thursday, May 11th. The stock was sold at an average price of $45.01, for a total value of $45,587,613.33. Following the transaction, the insider now owns 1,658,780 shares in the […]
Arcellx (NASDAQ:ACLX – Get Rating) had its price objective hoisted by Bank of America from $39.00 to $50.00 in a research note released on Wednesday morning, The Fly reports. ACLX has been the subject of a number of other reports. Needham & Company LLC lifted their price objective on shares of Arcellx from $35.00 to […]
Arcellx, Inc. (NASDAQ:ACLX – Get Rating) – Stock analysts at HC Wainwright lifted their Q2 2023 earnings per share estimates for shares of Arcellx in a research note issued on Tuesday, May 9th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn $3.52 per share for the quarter, up from their prior […]
Arcellx (NASDAQ:ACLX – Get Rating) had its price target raised by HC Wainwright from $40.00 to $49.00 in a research note published on Tuesday, The Fly reports. HC Wainwright also issued estimates for Arcellx’s Q2 2023 earnings at $3.52 EPS, Q3 2023 earnings at ($1.00) EPS, Q4 2023 earnings at ($1.04) EPS, FY2023 earnings at […]